Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most clinical indication claims are supported by the provided label excerpts (psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s disease). However, the excerpts provided do not establish “apremilast is the generic name” or “Otezla is the brand name” with the supplied text, so name/identity claims are unsupported based on the provided prescribing information excerpts.
Category Scores
Accurate Statements
Apremilast is used to treat psoriatic arthritis.
Section 1.1 Psoriatic Arthritis: OTEZLA/OTEZLA XR indicated for treatment of active psoriatic arthritis in labeled adult and pediatric populations.
Apremilast is used to treat plaque psoriasis.
Section 1.2 Plaque Psoriasis: OTEZLA/OTEZLA XR indicated for treatment of plaque psoriasis in labeled adults and pediatric patients who are candidates for phototherapy or systemic therapy.
Apremilast is used to treat Behçet’s disease–related oral ulcers.
Section 1.3 Oral Ulcers Associated with Behçet's Disease: OTEZLA/OTEZLA XR indicated for treatment of adult patients with oral ulcers associated with Behçet's Disease.
Unsupported Statements
Apremilast is the generic name of the drug.
The supplied label excerpts do not explicitly state that apremilast is the generic name of the labeled product(s).
The brand name of apremilast is Otezla.
The supplied label excerpts identify the labeled product as OTEZLA/OTEZLA XR, but do not explicitly state that OTEZLA is the brand name for apremilast.
Contradictions
Important Omissions
For plaque psoriasis and psoriatic arthritis, the label specifies additional eligibility criteria (e.g., age/weight cutoffs and that plaque psoriasis patients are candidates for phototherapy or systemic therapy). The claims provided omit these qualifiers.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The therapeutic indication statements are generally consistent with the label excerpts, but the identity (generic/brand) claims are unsupported by the provided excerpt text, and the indication qualifiers (age/weight and therapy candidacy criteria) are omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Name/identity assertions (generic vs brand naming) are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to labeled indications (psoriatic arthritis, plaque psoriasis in candidates for phototherapy/systemic therapy, and oral ulcers associated with Behçet’s disease) and include any material label qualifiers (age/weight cutoffs and therapy candidacy where relevant).